A retrospective analysis of the U.S. National Parkinson’s Foundation (NPF) database has found that clinical recognition of depression in Parkinson’s disease has improved but almost one-half of patients remain untreated (Bega et al. J Parkinsons Dis 2014; epublished July 17, 2014; free full text at http://iospress.metapress.com/content/92617284j0410402/fulltext.pdf). The study was part of the NPF’s Quality Improvement Initiative. Read More
Latest News
New data on first-line oral therapies in MS
November 4, 2015Long-term data
Safety studies
Comment: Dr. Mark S. Freedman, Director, Multiple Sclerosis Research Unit, The Ottawa Hospital, Ottawa, Canada
The 31st congress of the European Committee for Treatment and Research in MS (ECTRIMS) featured new research on current therapies for multiple sclerosis. In Canada, two oral therapies – teriflunomide and dimethyl fumarate (DMF) – are routinely used as first-line agents. The following summarizes key data for these two therapies presented at ECTRIMS. Read More
Late-breaking news at ECTRIMS 2015: ocrelizumab, minocycline and biotin
October 28, 2015European Committee for Treatment and Research in MS (ECTRIMS) 31st Congress – Barcelona, Spain, October 7-10, 2015 – The Late Breaking session at ECTRIMS 2015 was especially interesting this year as new data were presented on several novel MS treatments. Read More
Quality of life in schizophrenia: the QUALIFY trial
October 14, 2015QUALIFY study
Commentary from Dr. Ofer Agid
Considerable advances have been made in recent decades in the management of schizophrenia. A majority of first-episode patients achieve remission of psychotic symptoms within the first year of treatment (Lieberman et al. Arch Gen Psychiatry 1993;50:369-376), and early recurrence rates are low (Zipursky et al. Schizophr Res 2014;152:408-414). Read More